Its reduction by more than 50% in a mammalian subject, as required by claim 1, is therefore a precisely defined therapeutic application of dermal aspirin within the meaning of Article 52(4) EPC for the purpose of treating and preventing various diseases benefiting from suppression of thromboxane levels, for example, cerebrovascular and cardiovascular diseases such as ischemic heart disease.5.